Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment

Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseases with neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumab or ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Ye Jin, Hwang, Hyung Bin, Chung, Sung Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Ophthalmological Society 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958635/
https://www.ncbi.nlm.nih.gov/pubmed/24688262
http://dx.doi.org/10.3341/kjo.2014.28.2.177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958635/
https://www.ncbi.nlm.nih.gov/pubmed/24688262
http://dx.doi.org/10.3341/kjo.2014.28.2.177

Ejemplares similares